Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective

Pharmacogenetics, one of the cornerstones of personalized medicine, has the potential to change the way in which health care is offered by stratifying patients into various pretreatment categories, such as likely responders, likely non-responders or likely to experience adverse drug reactions. In order to advance drug development and regulatory science, regulatory agencies globally have promulgated guidelines on pharmacogenetics for nearly a decade. The aim of this article is to provide an overview of new guidelines for the implementation of pharmacogenetics in drug development from a multiregional regulatory perspective — encompassing Europe, the United States and Japan — with an emphasis on clinical pharmacokinetics.

[1]  E. Antman,et al.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.

[2]  J. Woodcock,et al.  Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective , 2004, Nature Reviews Drug Discovery.

[3]  L J Lesko,et al.  Pharmacogenomic-guided drug development: regulatory perspective , 2002, The Pharmacogenomics Journal.

[4]  K. Lindpaintner.  The impact of pharmacogenetics and pharmacogenomics on drug discovery , 2002, Nature Reviews Drug Discovery.

[5]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[6]  Jai Shah.  Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare , 2003, Nature Biotechnology.

[7]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[8]  Russ B. Altman,et al.  A Threat to Genomic Medicine , 2006 .

[9]  A. Barabasi,et al.  A Protein–Protein Interaction Network for Human Inherited Ataxias and Disorders of Purkinje Cell Degeneration , 2006, Cell.

[10]  David A. Katz,et al.  Defining drug disposition determinants: a pharmacogenetic–pharmacokinetic strategy , 2008, Nature Reviews Drug Discovery.

[11]  Amalia M. Issa,et al.  Ethical perspectives on pharmacogenomic profiling in the drug development process , 2002, Nature Reviews Drug Discovery.

[12]  M. Ritter,et al.  The ICln interactome , 2006, Acta physiologica.

[13]  Kenneth D. Mandl,et al.  Reestablishing the Researcher-Patient Compact , 2007, Science.

[14]  Christopher Lawrence,et al.  DEGENERATION , 2020, Side Effects May Include Strangers.

[15]  I. Zineh,et al.  Pharmacogenomics in the Assessment of Therapeutic Risks versus Benefits: Inside the United States Food and Drug Administration , 2011, Pharmacotherapy.

[16]  A. Y. Lu,et al.  Pharmacogenomics and Individualized Medicine , 2012 .

[17]  I. Kohane.  (Mis)treating the pharmacogenetic incidentalome , 2012, Nature Reviews Drug Discovery.

[18]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[19]  I. Kohane,et al.  Taxonomizing, sizing, and overcoming the incidentalome , 2012, Genetics in Medicine.

[20]  Fernando Rivadeneira,et al.  A genome-wide association study of acenocoumarol maintenance dosage. , 2009, Human molecular genetics.

[21]  R L Berg,et al.  Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing , 2010, Clinical pharmacology and therapeutics.

[22]  R. Weinshilboum,et al.  Pharmacogenomics: Bench to bedside. , 2005, Discovery medicine.

[23]  K. Hillgren,et al.  PhRMA White Paper on ADME Pharmacogenomics , 2008, Journal of clinical pharmacology.

[24]  D. Clapham,et al.  New mammalian chloride channel identified by expression cloning , 1992, Nature.

[25]  L. Trümper.  From bench to bedside , 2005, Medizinische Klinik.

[26]  R. Kim,et al.  Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. , 2006, Gastroenterology.

[27]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[28]  T. Lancet.  Moving toward precision medicine , 2011, The Lancet.

[29]  S. Duncan,et al.  Reappraisal of the historical selective pressures for the CCR5-Δ32 mutation , 2005, Journal of Medical Genetics.

[30]  Jiri Aubrecht,et al.  Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact , 2010, Nature Reviews Drug Discovery.

[31]  Kathryn A. Phillips,et al.  Measuring the value of pharmacogenomics , 2005, Nature Reviews Drug Discovery.

[32]  Fatih Ozsolak.  Third-generation sequencing techniques and applications to drug discovery , 2012, Expert opinion on drug discovery.

[33]  David E Hill,et al.  next-generation sequencing to generate interactome datasets , 2011 .

[34]  R. Weinshilboum,et al.  Pharmacogenomics: bench to bedside , 2004, Nature Reviews Drug Discovery.

[35]  Isaac S Kohane,et al.  Medicine. Reestablishing the researcher-patient compact. , 2007, Science.

[36]  S. Toyoshima,et al.  Current Japanese regulatory situations of pharmacogenomics in drug administration , 2008, Expert review of clinical pharmacology.

[37]  Shashi Amur,et al.  Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use , 2008, Pharmacotherapy.

[38]  A. Barabasi,et al.  Interactome Networks and Human Disease , 2011, Cell.

[39]  E. Antman,et al.  Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis , 2010, The Lancet.

[40]  L S Simon,et al.  The regulatory perspective , 2014, Journal of the peripheral nervous system : JPNS.

[41]  R. Altman,et al.  The incidentalome: a threat to genomic medicine. , 2006, JAMA.

[42]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[43]  A. Y. Lu,et al.  Pharmacogenetics, Pharmacogenomics, and Individualized Medicine , 2011, Pharmacological Reviews.

[44]  A. Daly,et al.  Pharmacogenetics and human genetic polymorphisms. , 2010, The Biochemical journal.

[45]  Magnus Ingelman-Sundberg,et al.  Pharmacogenomic biomarkers: new tools in current and future drug therapy. , 2011, Trends in pharmacological sciences.

[46]  G. Church,et al.  Correlation between transcriptome and interactome mapping data from Saccharomyces cerevisiae , 2001, Nature Genetics.

[47]  HLA-DRB1 genes and extraarticular rheumatoid arthritis , 2006, Arthritis research & therapy.

[48]  Federico Goodsaid,et al.  Evolution of biomarker qualification at the health authorities , 2010, Nature Biotechnology.

[49]  A. Barabasi,et al.  An empirical framework for binary interactome mapping , 2008, Nature Methods.

[50]  Hyeong Jun An,et al.  Estimating the size of the human interactome , 2008, Proceedings of the National Academy of Sciences.

[51]  S. L. Wong,et al.  Towards a proteome-scale map of the human protein–protein interaction network , 2005, Nature.

[52]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[53]  F. Schmidt.  Meta-Analysis , 2008 .

[54]  Mikko Niemi,et al.  SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.

[55]  Michel Eichelbaum,et al.  Pharmacogenomics and individualized drug therapy. , 2006, Annual review of medicine.

[56]  Richard M Weinshilboum,et al.  Genomics and drug response. , 2011, The New England journal of medicine.

[57]  Ara Darzi,et al.  Preparing for precision medicine. , 2012, The New England journal of medicine.